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A single capsule formulation of RHB-104 
demonstrates higher anti-microbial growth 
potency for effective treatment of Crohn’s 
disease associated with Mycobacterium avium 
subspecies paratuberculosis
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Abstract 
Background: Most recently we reported that RHB‑104 triple antibiotics combination in culture is bactericidal and 
should be effective for treatment of Crohn’s disease (CD)‑associated with Mycobacterium avium subspecies paratu-
berculosis (MAP) (Alcedo et al. in Gut Pathog 14:32, 2016). The combination exhibited unique synergistic antimicrobial 
growth activity. The proprietary RHB‑104 capsule formulation contains active ingredients (63.3 % Clarithromycin (CLA), 
6.7 % Clofazimine (CLO) and 30 % Rifabutin (RIF)). In our earlier study, we could not dissolve the proprietary RHB‑104 
capsule formulation in one compatible solvent. Consequently, we re‑created RHB‑104 analog by adding appropriate 
concentrations of each of the three antibiotics into the cultures. The Minimum inhibitory concentration (MIC) for RHB‑
104 analog, CLA, CLO, RIF, CLA‑CLO, CLA‑RIF, CLO‑RIF and their individual solvents were reported earlier (Alcedo et al. 
in Gut Pathog 14:32, 2016). In this study, we succeeded in dissolving the proprietary RHB‑104 capsule formulation in a 
single proprietary solvent. This study is designed to compare of the MIC the proprietary RHB‑104 capsule formulation 
to RHB‑104 analog against MAP and other microorganisms.
Methods: BD Bactec™ MGIT™ Para‑TB medium (Sparks, MD) system was used to determine the MIC of the propri‑
etary RHB‑104 capsule formulation and RHB‑104 analog and their solvents against MAP and several other microorgan‑
isms. The final concentration of solvents used to dissolve all the drugs were ≤0.5 % (v/v).
Results: The MIC for the RHB‑104 proprietary solvent against MAP was consistent against all microorganisms tested 
in the study at 12.5 % (v/v). The MIC for the proprietary RHB‑104 capsule formulation was similar to RHB‑104 analog 
against several MAP clinical strains with MIC ≤ 0.2 μg/mL. The MIC for the proprietary RHB‑104 capsule formulation 
was at 2.0 μg/mL against MAP strain MS 137 and M. avium strain JF7 compared to 4.0 ug/mL for RHB‑104 analog. 
Similarly, the MIC of RHB‑104 formulation capsule was significantly lower than RHB‑104 analog against M. tuberculosis 
HR237, M. fortuitism subspecies fortuitum, M. smegmatis ATCC 27199, Staphylococcus aureus ATCC 25923 and Listeria 
monocytogenes ATCC 19112.
Conclusion: The data demonstrated that the proprietary RHB‑104 capsule formulation is more potent in culture 
against Mycobacteria and other microorganisms especially those with MIC >0.2. Formulation of multi‑drugs in a 
single capsule results in potent synergistic anti‑microbial activity far exceeds treatment the culture with multi‑individ‑
ually dissolved drugs. RHB‑104 capsule formulation should be more effective to eradicate MAP infection in patients 
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Background
The current treatment guidelines of Crohn’s disease (CD) 
include immunosuppressants, anti-inflammatory drugs, 
nutritional therapy and antibiotics. Mycobacterium 
avium subspecies paratuberculosis (MAP) was isolated 
from intestinal tissues, milk and blood samples from CD 
patients at a higher frequency than controls [1–3]. Other 
microorganisms have been associated with CD such as 
Listeria monocytogenes, Staphylococcus aureus, Klebsiella 
pneumoniae and enteropathogenic Escherichia coli [4, 5]. 
CD patients treated with prolonged combination of mac-
rolide-based anti-mycobacterial regimens in randomized 
clinical trials have achieved reversal of CD symptoms [6].
Most recently we evaluated the anti-microbial effect 
of three antibiotics regimen in the proprietary RHB-
104 capsule formulation (RedHill Biopharma) in culture 
against 35 clinical MAP strains and other mycobacterial 
strains [7]. We determined the MIC for individual, and 
dual and triple combinations of the three antibiotics and 
their solvents [7] and have concluded that the triple com-
bination of RHB-104 analog [a mixture of individually 
dissolved 63.3  % Clarithromycin (CLA), 6.7  % Clofazi-
mine (CLO) and 30 % Rifabutin (RIF)] were more effec-
tive against MAP growth than when the cultures were 
treated with single or dual antibiotics dosages.
This study is focused on dissolving the proprietary 
RHB-104 capsule formulation in a solvent followed by 
determination of its MIC compared to RHB-104 analog 
against MAP and other microorganisms.
Results
In this study, we have successfully dissolved the pro-
prietary RHB-104 capsule formulation in one compat-
ible solvent. Due to proprietary ownership, RHB-104 
capsule formulation solvent information can be 
requested directly from RedHill Biopharma. The MIC 
of the proprietary RHB-104 solvent against MAP 
and other microorganisms was at 12.5  % (v/v). The 
proprietary RHB-104 capsule formulation inhibitory 
effect on microorganisms with MIC ≤0.20  μg/mL was 
similar to RHB-104 analog (Fig.  1). However, the MIC 
for proprietary RHB-104 capsule formulation was at 
2.0 μg/mL compared to 4.0 μg/mL for RHB-104 analog 
against MAP strain MS 137 from CD patient and M. 
avium strain JF7 isolated from a HIV patient. The pro-
prietary RHB-104 capsule formulation was more potent 
than RHB-104 analog against M. fortuitum subspecies 
fortuitum (MIC of 10 vs 15  μg/mL), M. tuberculosis 
strain HR237 (MIC of 5 vs 10  μg/mL), M. smegmatis 
ATCC 27199 (MIC of 0.5 vs 6 μg/mL), S. aureus ATCC 
25923 (MIC of 0.125 vs 0.25  μg/mL), and L. monocy-
togenes ATCC 19112 (MIC of 0.25 vs 0.5 μg/mL). Inter-
estingly, the MIC for CLA (63  % of the proprietary 
RHB-104 capsule formulation) against S. aureus and L. 
monocytogenes was at 1.5  μg/mL. Table  1 summarizes 
MIC values for both the proprietary RHB-104 capsule 
formulation and RHB-104 analog against several micro-
organisms used in this study. There was no significant 
inhibitory effect in culture on the growth of K. pneu-
monia (ATCC 13883) and plasmid-harboring E. coli 
(MIC  >40  μg/mL). The final concentration of solvents 
used to dissolve all the drugs in the study were ≤0.5 % 
(v/v) and had no effect on bacterial growth in cultures. 
Conclusion
The ability to evaluate the proprietary RHB-104 capsule 
formulation dissolved in one compatible solvent against 
broad spectrum of microorganisms demonstrated that 
this investigational single capsule formulation is more 
potent against Mycobacteria and other microorganisms 
associated with CD than previously determined. The 
study clearly concludes that the synergistic effect between 
CLA, CLO and RIF triple formulation in a single capsule 
is strong and therefore, favoring formulation-approach 
treatment. The data also suggests that the formulation 
approach might be used to re-evaluate antibiotics that 
with CD. The study provides evidence that combining weak antibiotics in one formulation might be the new silver 
bullet to combat bacteria.
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have been declared as ineffective when used individually. 
The study strongly suggest that the proprietary RHB-104 
capsule formulation should be more effective to eradicate 
MAP infection than regimens with multi-individualized 
antibiotics. Ultimately, one single capsule formulation 
treatment should enhance compliance and clinical out-
come for CD patients.
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CD: Crohn’s disease; MAP: Mycobacterium avium subspecies paratuberculosis; 
CLA: clarithromycin; CLO: clofazimine; RIF: cifabutin; MIC: minimum inhibitory 
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Fig. 1 Effect of the proprietary RHB‑104 capsule formulation and RHB‑104 analog on culture growth of MAP MS 137, M. smegmatis, L. monocy-
togenes and S. aureus. * MIC level in μg/mL. ** The proprietary RHB‑104 capsule formulation dissolved in one compatible solvent. *** RHB‑104 
analog (a mixture of individually dissolved 63.3 % Clarithromycin (CLA), 6.7 % Clofazimine (CLO) and 30 % Rifabutin (RIF), equal to  %composition in 
the proprietary RHB‑104 capsule formulation)
Table 1 MIC of  the proprietary RHB-104 capsule formula-
tion and RHB-104 analog
All cultures were performed in duplicates and have been repeated three times
a RHB-104 analog where the 3 drugs dissolved individually were combined 
in one solution at their proprietary RHB-104 capsule formulation composition 
percentage
b Proprietary RHB-104 capsule formulation was dissolved in one compatible 
solvent







MAP MS 137 4.0 2.0
M. avium—JF7 4.0 2.0
M. fortuitum ss fortuitum 15 10
M. tuberculosis HR237 10 5.0
M. smegmatis ATCC 27199 6.0 0.125
S. aureus ATCC 25923 0.25 0.125
L. monocytogenes ATCC 19112 0.5 0.25
K. pneumonia ATCC 13883 >40 >40
Recombinant E. coli >40 >40
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